Table 3.
Application of 2016 Chinese CAP guidelines in hospitalized patients over 65 years with risk factors of Pseudomonas aeruginosa infection (n = 815)
| Regimen | General ward inpatients (n = 722) | ICU patients (n = 93) |
|---|---|---|
| Consistent with guideline | 348(48.2) | 22(23.7) |
| Antipseudomonal β-lactam | 247(34.2) | 0(0) |
| Antipseudomonal fluoroquinolone | 85(11.8) | 0(0) |
| Antipseudomonal β-lactam + macrolide | 16(2.2) | 0(0) |
| Antipseudomonal β-lactam +fluoroquinolone | 0(0) | 21(22.6) |
| Antipseudomonal β-lactam+ aminoglycosides | 0(0) | 1(1.1) |
| Undertreated by guideline | 165(22.9) | 69(74.2) |
| β-lactam | 132(18.3) | 10(10.8) |
| Antipseudomonal β-lactam | 0(0) | 32(34.4) |
| Macrolide | 5(0.7) | 0(0) |
| β-lactam + macrolide | 23(3.2) | 1(1.1) |
| Antipseudomonal fluoroquinolone +/− β-lactam/ other | 0(0) | 9(9.7) |
| Antipseudomonal β-lactam + macrolide | 0(0) | 4(4.3) |
| Antipseudomonal fluoroquinolone + macrolide | 0(0) | 2(2.2) |
| Other combination | 5(0.7) | 11(11.8) |
| Overtreated by guideline | 209(28.9) | 2(2.2) |
| Antipseudomonal β-lactam + antipseudomonal fluoroquinolone + macrolide /other | 6(0.8) | 2(2.2) |
| Antipseudomonal β-lactam + antipseudomonal fluoroquinolone | 96(13.3) | 0(0) |
| Antipseudomonal fluoroquinolone +β-lactam | 65(9.0) | 0(0) |
| Antipseudomonal fluoroquinolone+ macrolide | 5(0.7) | 0(0) |
| Antipseudomonal fluoroquinolone + other | 13(1.8) | 0(0) |
| Antipseudomonal β-lactam + other | 24(3.3) | 0(0) |
Data on empirical antimicrobial regimens in 12 patients were missing
other = imidazoles, lincomycin, fosfomycin, glycopeptides and antifungal agents